Biotechnology and Pharma

The entire drug discovery process is manufacturing and operations heavy. As new manufacturing processes are introduced, and complex new supply chain ecosystems evolve, it will be difficult for biopharma companies to produce high yields in the drug manufacturing process while keeping costs down.

Though pharmaceutical companies, research labs, biobanks, and universities all play a major role in drug discovery and development, creating a well coordinated ecosystem for information exchange is challenging, and it often prohibits or delays drug discovery innovation.

While cloud computing, big data, machine learning, and the IoT are benefitting the biopharma industry to a large extent, each individual technology often creates additional data silos, restricting the benefit of the overall data ecosystem.

The pharmaceutical industry is one of the most strictly regulated industries in the world. IP protection, drug and device safety, counterfeit drug threat, and personally identifiable information (PII) protection are some of the biggest concerns of biopharma companies.

In recent years, the biopharma industry has experienced some of the most M&A deals, and some of the largest. Almost all post merger entities face challenges with operational complexity, value creation, risk management issues, cost overrun, and other issues.